Complizen Learn

The FDA just mentioned AI in a warning letter. Before you panic, read what it actually said. A lot of people in regulated industries are skeptical of AI. Honestly, they are not wrong. There is already too much noise. Too many tools overpromising and underdelivering. So when FDA mentions AI in a warning letter, people pay attention. They should. But for the right reason. FDA did not reject AI. FDA rejected blind reliance. In its April 2026 warning letter to Purolea Cosmetics L

FDA can help you sell beyond America A lot of international manufacturers still ask the wrong question: “Is FDA clearance worth it if the U.S. is not our main market?” That is too narrow. Yes, the U.S. matters. It is still the world’s largest medical device market, with about 40% of global share . But for some manufacturers, the bigger value of FDA is not just access to America. It is what FDA helps you do outside America: sell in markets with stringent regulatory requiremn

International medical device manufacturers often run into the same avoidable U.S. market-entry mistakes: assuming CE-mark experience will translate cleanly to FDA, choosing the wrong predicate strategy, trying to reuse EU clinical data without reframing it for substantial equivalence, misunderstanding when a U.S. Agent is needed, missing U.S.-specific testing expectations, underestimating the burden of Additional Information requests, overlooking remaining QMSR gaps after ISO

Tariffs are usually discussed in terms of trade policy, manufacturing costs, and geopolitics. But in the global medical device industry, they may be doing something else entirely. They are quietly creating the next wave of companies entering the U.S. healthcare market. Across Southeast Asia and other emerging manufacturing hubs, medical device manufacturers that historically focused on contract production are beginning to ask a different question: What if we sold directly int

When Kintsugi shut down, a lot of people filed it under “clinical AI is hard.” That’s true, but incomplete. Kintsugi is a clean case study in something more important, the regulatory path can be scientifically valid and still economically fatal. You can build a real product, run serious pilots, pursue FDA the right way, and still lose because your runway is measured in months while regulatory certainty is measured in years. If you build in medtech, this is not a rare edge cas

AI can speed up 510(k) predicate research by 70-80%, find relevant FDA guidance in minutes instead of hours, and organize evidence trails automatically. But AI cannot make regulatory strategy decisions, replace required testing, or take accountability for submission content. Best results: Use AI for research-heavy tasks (finding predicates, FDA guidance, standards), pair with regulatory consultant for strategy and review. Cost comparison: AI tools $200-$2K/month vs. consultan

For many international medical device manufacturers, entering the US market carries a particular kind of weight. The FDA is seen as conservative. Documentation is assumed to be heavier. Reviews are thought to be unpredictable. So the US often feels like a fundamentally harder market. In practice, most of the difficulty teams encounter does not come from stricter rules or higher scientific standards. It comes from confusion about where to start, what applies, and how to transl

Most people assume regulatory work is slow because the rules are hard. The requirements are strict, the stakes are high, and mistakes are costly. Long timelines feel unavoidable. In practice, that’s not what actually slows teams down. Regulatory work isn’t slow because it’s complex. It’s slow because of how information is handled. Key takeaways Regulatory teams lose time searching instead of making decisions Scattered information makes work harder to defend and repeat Small g

CMS New Technology Add-on Payment (NTAP) is the fastest path to Medicare reimbursement for by providing additional Medicare payments above standard DRG rates for qualifying new medical technologies. AI devices must meet three criteria: newness (within 2-3 years), cost adequacy, and substantial clinical improvement. NTAP can last up to 3 years (depending on newness) and can support adoption by reducing financial friction. This guide covers everything you need to know about NTA

The EU AI Act is a risk-based regulation requiring AI medical devices to undergo dual compliance, single integrated CE: NB assesses AIA + MDR/IVDR together. High-risk AI systems need notified body assessment, AI literacy training, and enhanced post-market surveillance. Medical devices get 36 months to comply (until August 2027), but AI literacy requirements already apply from February 2025. This guide covers everything you need to know about EU AI Act compliance for medical d

EU AI Act requires separate AI system certification alongside medical device approval, with 36-month implementation timeline. FDA's PCCP allows pre-approved change plans to modify AI devices without new submissions. Companies targeting both markets need dual strategies - EU compliance for safety-critical changes, PCCP for iterative improvements in the US. Here's how to choose the optimal regulatory strategy for your AI medical device's global success. The $500K+ Decision Ever

IMDRF is the global forum harmonizing medical device regulations across major markets (FDA, MHRA, Health Canada, EU). On Jan, 2025, IMDRF finalized N88 (10 Good Machine Learning Practice principles for AI/ML devices) and N81 (characterization considerations for medical-device software and software-specific risk). IMDRF documents guide—but don’t replace—jurisdictional rules; adoption timing varies by regulator. This guide covers everything you need to know about IMDRF's impact

Medical device companies expanding globally face a critical strategic decision: which regulatory pathway offers the fastest, most cost-effective route to market? EU MDR typically requires 12-18 months and $500K-$2M for CE marking through Notified Body assessment, while FDA 510(k) averages 6-12 months and $1M-$6M but offers faster market access. EU MDR provides broader global market acceptance (27 EU countries + many international markets), while FDA 510(k) is primarily US-foc

Medical device startups have 8 primary funding sources: government grants ($305K-$3M, non-dilutive), angel investors ($50K-$2M, 10-25% equity), venture capital ($1M-$100M+, 15-30% equity per round), crowdfunding ($50K-$1M, variable terms), accelerators ($25K-$250K + mentorship), corporate partnerships, revenue-based financing, and bootstrapping. The smart play is sequencing: validate with grants, bridge with angels, then scale with venture—layering in partnerships or revenue-

Medical device development costs vary by classification: Class I ($200K-$2M), Class II ($2M-$30M), and Class III ($5M-$119M+). Major expenses include clinical trials (40-60% of budget), regulatory activities (10-15%), manufacturing setup (15-25%), and commercialization (10-20%). Timeline spans 1-7 years depending on complexity and pathway. The #1 question every medtech entrepreneur asks: "How much funding do I actually need?" The answer depends on your device classification,

FDA is replacing 21 CFR 820 (Quality System Regulation) with the Quality Management System Regulation (QMSR) on February 2, 2026,...

An FDA Warning Letter is a public advisory notice that cites significant violations and requests a written response—typically within 15 working days. It signals FDA expects prompt corrective action; unresolved issues can escalate to injunction, seizure, or import actions. Treat it as a structured trigger for rapid remediation, not a debate. Top violations include CAPA failures, design control deficiencies, and complaint handling issues. This comprehensive guide provides medte

Most SaMD 510(k)s hit a first-cycle Additional Information (AI) letter , not a final rejection. The recurring issues: missing...

Sam Altman’s June 10, 2025 essay, “ The Gentle Singularity ,” sketches a near-term AI timeline—2025 agents doing real cognitive work,...

In 2025, FDA reviews a risk-based software evidence package per the Device Software Functions (DSF) guidance: choose Basic or Enhanced documentation, supply V&V protocols/results (unit/integration/system as applicable), traceability to hazards/requirements, version history, and unresolved anomalies. AI adds lifecycle docs per the 2025 AI draft, and cyber devices need the 2025 cybersecurity artifacts. eSTAR is required for 510(k) and required for De Novo on Oct 1, 2025. Why So